ArticleCancer research communications2025
Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis.
Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Abstract: Limited knowledge exists on the prevalence of comorbidity among pediatric patients diagnosed with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL). To determine the prevalence of comorbidities present within 3 months before diagnosis among pediatric patients with ALL/LL and to examine if the prevalence varies by age, biological sex at birth, and race/ethnicity, we analyzed data of patients diagnosed with ALL/LL at ≤21 years of age from January 1, 2005, to June 30, 2020 (n = 5,455), using electronic health records data from the TriNetX Research Network database. Comorbidities examined included pulmonary, cardiac, cerebrovascular, vascular, developmental, immune, metabolic, infectious, genitourinary, digestive, muscle and connective tissue and central and peripheral nervous system conditions. Overall, the prevalence of comorbidity was 34.1% (n = 1,904), with significant differences observed based on sex and race/ethnicity. Females had a higher prevalence at 36.6% compared with males at 33.6% (P = 0.024). Similarly, non-Hispanic White patients had a higher prevalence of 37.5% compared with 33.1% in other racial/ethnic groups (P < 0.001). Analyses of specific comorbidities revealed notable differences in the prevalence of infectious diseases by biological sex at birth (female: 9.7%, male: 7.0%; P < 0.001) and digestive diseases by age at diagnosis (≤10 years: 13.8%, >10 years: 10.4%; P < 0.001). Although the overall prevalence of comorbidity at diagnosis showed minor differences across groups, disparities exist for specific comorbidities with females and younger patients having a higher prevalence of infectious diseases and digestive tract diseases, respectively. Future studies are needed to evaluate if these differences contribute to the disparities in treatment outcomes. Significance: Among pediatric patients with ALL/LL, significant disparities were found for specific comorbidities, particularly among females and younger patients who had higher rates of digestive tract diseases and infectious diseases. These findings are important as comorbidities can be considered in clinical decision-making in the management and treatment of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.